Literature DB >> 23064035

Successful treatment by adding duloxetine to pregabalin for peripheral neuropathy induced by paclitaxel.

Motoyasu Takenaka1, Hiroki Iida, Shigemi Matsumoto, Shinobu Yamaguchi, Noritaka Yoshimura, Maki Miyamoto.   

Abstract

Although paclitaxel is a commonly used anticancer drug, peripheral neuropathy may develop as a side effect. Worsening of the symptoms with time may cause patients who receive paclitaxel to give up their chemotherapy. Duloxetine, a serotonin- and norepinephrine-reuptake inhibitor, has been used to treat peripheral neuropathic pain. We report the case of a 68-year-old man with gastric cancer, who underwent gastrectomy and then received 8 cycles of chemotherapy involving weekly administrations of paclitaxel. Under this paclitaxel treatment, he complained of severe peripheral neuropathy, leading to a diminished quality of life. Following treatment with a combination of duloxetine and pregabalin, a remission of his symptoms was achieved. Duloxetine plus pregabalin therapy may be useful for the peripheral neuropathy induced by paclitaxel.

Entities:  

Keywords:  cancer; chemotherapy; duloxetine; paclitaxel; peripheral neuropathy; pregabalin

Mesh:

Substances:

Year:  2012        PMID: 23064035     DOI: 10.1177/1049909112463416

Source DB:  PubMed          Journal:  Am J Hosp Palliat Care        ISSN: 1049-9091            Impact factor:   2.500


  9 in total

Review 1.  Pregabalin for chemotherapy-induced neuropathy: background and rationale for further study.

Authors:  Mellar Davis; Charles Loprinzi
Journal:  Support Care Cancer       Date:  2022-08-11       Impact factor: 3.359

2.  Effect of duloxetine in Japanese patients with chemotherapy-induced peripheral neuropathy: a pilot randomized trial.

Authors:  Yasuo Hirayama; Kunihiko Ishitani; Yasushi Sato; Satoshi Iyama; Kohichi Takada; Kazuyuki Murase; Hiroyuki Kuroda; Yasuhiro Nagamachi; Yuichi Konuma; Akihito Fujimi; Tamotsu Sagawa; Kaoru Ono; Hiroto Horiguchi; Takeshi Terui; Kazuhiko Koike; Toshiro Kusakabe; Tsutomu Sato; Rishu Takimoto; Masayoshi Kobune; Junji Kato
Journal:  Int J Clin Oncol       Date:  2015-03-12       Impact factor: 3.402

3.  Efficacy and safety of duloxetine in Chinese breast cancer patients with paclitaxel-induced peripheral neuropathy.

Authors:  Jiani Wang; Qing Li; Binghe Xu; Tongtong Zhang; Shanshan Chen; Yang Luo
Journal:  Chin J Cancer Res       Date:  2017-10       Impact factor: 5.087

Review 4.  Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature.

Authors:  Andreas A Argyriou; Athanasios P Kyritsis; Thomas Makatsoris; Haralabos P Kalofonos
Journal:  Cancer Manag Res       Date:  2014-03-19       Impact factor: 3.989

5.  Survey of the management of chemotherapy-induced peripheral neuropathy in Japan: Japanese Society of Medical Oncology.

Authors:  Yasuo Hirayama; Jiichiro Sasaki; Hirotoshi Dosaka-Akita; Kunihiko Ishitani
Journal:  ESMO Open       Date:  2016-05-13

6.  New Insights into Potential Prevention and Management Options for Chemotherapy-Induced Peripheral Neuropathy.

Authors:  Janet Schloss; Maree Colosimo; Luis Vitetta
Journal:  Asia Pac J Oncol Nurs       Date:  2016 Jan-Mar

7.  Analgesic effects of a hydro-ethanolic whole plant extract of Synedrella nodiflora (L.) Gaertn in paclitaxel-induced neuropathic pain in rats.

Authors:  Patrick Amoateng; Samuel Adjei; Dorcas Osei-Safo; Kennedy Kwami Edem Kukuia; Irene Akwo Kretchy; Joseph Adusei Sarkodie; Benoit Banga N'Guessan
Journal:  BMC Res Notes       Date:  2017-06-26

8.  Bibliometric Analysis Reveals a 20-Year Research Trend for Chemotherapy-Induced Peripheral Neuropathy.

Authors:  Jialin Gu; Miao Hu; Zhancheng Gu; Jialin Yu; Yi Ji; Lingchang Li; Canhong Hu; Guoli Wei; Jiege Huo
Journal:  Front Neurol       Date:  2022-02-08       Impact factor: 4.003

9.  Effect of serotonin-norepinephrine reuptake inhibitors for patients with chemotherapy-induced painful peripheral neuropathy: A meta-analysis.

Authors:  Soo Youn Song; Young Bok Ko; Hyeun Kim; Geon Woo Lee; Jung Bo Yang; Ha Kyun Chang; Sang Mi Kwak; Jaeyun Jung; Siyeo Lee; Sun Yeul Lee; Heon Jong Yoo
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.817

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.